Patents by Inventor Jacek OLCZAK
Jacek OLCZAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150362Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease, disorder, or condition associated with USP7 activity.Type: ApplicationFiled: August 25, 2023Publication date: May 9, 2024Inventors: Jacek Chrzanowski, Anna Gzik, Joanna Brzezinska, Robert Koralewski, Lukasz Joachimiak, Karolina Rozga, Szymon Kapuscinski, Bartlomiej Borek, Mateusz Urban, Sylwia Ciastek-Iskrzycka, Julita Nowicka, Kamil Lisiecki, Roman Blaszczyk, Adam Golebiowski, Jacek Olczak
-
Publication number: 20230348516Abstract: This invention is related to novel inhibitors of chitinase-like protein YKL-40 and their therapeutic applications. Such YKL-40 inhibitors are of use as therapeutic agents for the treatment a variety of diseases and disorders, including cancers, inflammation, and pulmonary diseases.Type: ApplicationFiled: April 28, 2023Publication date: November 2, 2023Inventors: Wojciech Czestkowski, Marzena Mazur, Przemyslaw Wanat, Gleb Andryianau, Piotr Niedziejko, Michal Kowalski, Mariusz Marek Gruza, Kamil Lisiecki, Piotr Pomaransk, Damian Kusmirek, Diana Papiernik, Katarzyna Drzewicka, Katarzyna Piwowar, Katarzyna Krysztofiak, Jacek Olczak, Adam Golebiowski, Lukasz Krzeminski, Agnieszka Bartoszewicz
-
Publication number: 20230278996Abstract: Disclosed are novel assays for screening active compounds interfering with interaction between chitinase-like protein YKL-40 and chitin oligomers, as well as interfering with interaction between chitinase-like protein YKL-40 and heparan sulfate. Moreover, disclosed are novel active compounds identified by these assays as inhibitors of chitinase-like protein YKL-40, their therapeutic applications, and their use in biosensors measuring the level of chitinase-like protein YKL-40 in biological samples.Type: ApplicationFiled: March 3, 2023Publication date: September 7, 2023Inventors: Lukasz Krzeminski, Wojciech Czestkowski, Marzena Mazur, Gleb Andryianau, Sylwia Olejniczak, Michal Czeslaw Piotrowicz, Robert Koralewski, Elzbieta Pluta, Krzysztof Matyszewski, Michal Kowalski, Barbara Dymek, Rafal Koziel, Jacek Olczak, Adam Golebiowski, Agnieszka Bartoszewicz, Katarzyna Krysztofiak
-
Publication number: 20230219973Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease, disorder, or condition associated with USP7 activity.Type: ApplicationFiled: December 22, 2022Publication date: July 13, 2023Inventors: Jacek CHRZANOWSKI, Julita NOWICKA, Lukasz JOACHIMIAK, Robert KORALEWSKI, Sylwia OLEJNICZAK, Marzena MAZUR, BartlomieJ BOREK, Anna GZIK, Krzysztof MATYSZEWSKI, Sylwia CIASTEK-ISKRZYCKA, Piotr NIEDZIEJKO, Angelika MUCHOWICZ, Zbigniew ZASLONA, Roman BLASZCZYK, Jacek OLCZAK, Adam GOLEBIOWSKI
-
Patent number: 11638707Abstract: Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.Type: GrantFiled: July 15, 2020Date of Patent: May 2, 2023Assignee: Molecure S.A.Inventors: Marzena Mazur, Gleb Andryianau, Lukasz Joachimiak, Wojciech Czestkowski, Michal Kowalski, Piotr Niedziejko, Sylwia Olejniczak, Krzysztof Matyszewski, Robert Koralewski, Jacek Olczak, Adam Golebiowski, Agnieszka Bartoszewicz
-
Publication number: 20220204530Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.Type: ApplicationFiled: December 22, 2021Publication date: June 30, 2022Inventors: Anna Gzik, Jacek Chrzanowski, Bartlomiej Borek, Roman Blaszczyk, Jacek Olczak, Adam Golebiowski, Marcin Mikolaj Grzybowski, Paulina Pomper
-
Publication number: 20210260019Abstract: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.Type: ApplicationFiled: February 5, 2021Publication date: August 26, 2021Inventors: Roman Blaszczyk, Joanna Brzezinska, Anna Gzik, Adam Golebiowski, Julita Nowicka, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Krzysztof Matyszewski, Jacek Olczak
-
Patent number: 10912755Abstract: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.Type: GrantFiled: August 14, 2019Date of Patent: February 9, 2021Assignee: OncoArendi Therapeutics S.A.Inventors: Roman Blaszczyk, Joanna Brzezinska, Anna Gzik, Adam A. Golebiowski, Julita Nowicka, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Krzysztof Matyszewski, Jacek Olczak
-
Patent number: 10851099Abstract: The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.Type: GrantFiled: March 29, 2019Date of Patent: December 1, 2020Assignee: OncoArendi Therapeutics S.A.Inventors: Roman Blaszczyk, Anna Gzik, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Julita Nowicka, Jacek Chrzanowski, Joanna Brzezinska, Adam Golebiowski, Jacek Olczak, Marcin Mikolaj Grzybowski, Jolanta Peczkowicz-Szyszka
-
Publication number: 20190300525Abstract: The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.Type: ApplicationFiled: March 29, 2019Publication date: October 3, 2019Inventors: Roman Blaszczyk, Anna Gzik, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Julita Nowicka, Jacek Chrzanowski, Joanna Brzezinska, Adam Golebiowski, Jacek Olczak, Marcin Mikolaj Grzybowski, Jolanta Peczkowicz-Szyszka
-
Patent number: 10391077Abstract: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.Type: GrantFiled: May 2, 2017Date of Patent: August 27, 2019Assignee: OncoArendi Therapeutics S.A.Inventors: Roman Blaszczyk, Joanna BrzeziĆska, Anna Gzik, Adam Golebiowski, Julita Nowicka, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Krzysztof Matyszewski, Jacek Olczak
-
Patent number: 10329310Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The inventions also provides pharmaceutical compositions and methods for using the inventive compounds for treating or preventing a disease or condition associated with arginase activity.Type: GrantFiled: December 22, 2015Date of Patent: June 25, 2019Assignee: Onco Arendi Therapeutics S.A.Inventors: Roman Blaszczyk, Joanna Brzezinska, Adam A. Golebiowski, Jacek Olczak
-
Patent number: 10214531Abstract: The invention provides novel substituted amino triazoles of Formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, as well as pharmaceutical compositions comprising the same. The compounds of the invention are inhibitors of acidic mammalian chitinase (AMCase) and are useful, in a non-limiting embodiment, for treating asthma. The invention further provides methods of using compounds and/or compositions of the invention to treat asthma and/or to monitor asthma treatment.Type: GrantFiled: December 19, 2014Date of Patent: February 26, 2019Assignee: Institute for Drug Discovery, LLCInventors: Michael L. Corman, William M. Hungerford, Adam Golebiowski, Raymond P. Beckett, Marzena Mazur, Sylwia Olejniczak, Jacek Olczak
-
Publication number: 20180009830Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The inventions also provides pharmaceutical compositions and methods for using the inventive compounds for treating or preventing a disease or condition associated with arginase activity.Type: ApplicationFiled: December 22, 2015Publication date: January 11, 2018Inventors: Roman BLASZCZYK, Joanna BRZEZINSKA, Adam A. GOLEBIOWSKI, Jacek OLCZAK
-
Publication number: 20170319536Abstract: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.Type: ApplicationFiled: May 2, 2017Publication date: November 9, 2017Inventors: Roman Blaszczyk, Joanna Brzezinska, Anna Gzik, Adam Golebiowski, Julita Nowicka, Bartlomiej Borek, Marek Dziegielewski, Karol Jedrzejczak, Krzysztof Matyszewski, Jacek Olczak
-
Patent number: 9611514Abstract: The present invention relates to a method for selection or screening of hDIS3 PIN domain inhibitors, yeast strain and cell line used in such methods It also relates to new therapeutic agents selected hDIS3 PIN domain inhibitors and uses thereof in the treatment of cancers having mutations inhDIS3 RNB domain, especially multiple myeloma. The invention also relates to composition comprising new therapeutic agent hDIS3 PIN domain inhibitor and method for inducing synthetic lethality in a cancer cell.Type: GrantFiled: May 20, 2014Date of Patent: April 4, 2017Assignees: INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK, ONCOARENDI THERAPEUTICS SP ZOO, MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ W WARSZAWIEInventors: Andrzej Dziembowski, Rafal Tomecki, Karolina Drazkowska, Roman Szczesny, Krystian Stodus, Weronika Jonko, Marcin Nowotny, Adam Golebiowski, Jacek Olczak
-
Publication number: 20160297823Abstract: Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.Type: ApplicationFiled: December 19, 2014Publication date: October 13, 2016Inventors: Michael L. CORMAN, William M. HUNGERFORD, Adam GOLEBIOWSKI, Raymond P. BECKETT, Marzena MAZUR, Sylwia OLEJNICZAK, Jacek OLCZAK
-
Patent number: 9440953Abstract: Disclosed are amino triazole compounds substituted by a carboxylate functional group or an bioisosteric polar functional group. Compounds having the carboxylate moiety or carboxylate bioisostere inhibit acidic mammalian chitinase. Also provided are methods of using the compounds to treat asthma reactions caused by allergens.Type: GrantFiled: December 4, 2015Date of Patent: September 13, 2016Assignee: OncoArendi Therapeutics Sp. z o.o.Inventors: Adam Golebiowski, Robert Koralewski, Wojciech J. Czestkowski, Krzysztof Matyszewski, Sylwia Olejniczak, Jacek Olczak, Paul Beckett
-
Publication number: 20160176843Abstract: Disclosed are amino triazole compounds substituted by a carboxylate functional group or an bioisosteric polar functional group. Compounds having the carboxylate moiety or carboxylate bioisostere inhibit acidic mammalian chitinase. Also provided are methods of using the compounds to treat asthma reactions caused by allergens.Type: ApplicationFiled: December 4, 2015Publication date: June 23, 2016Inventors: Adam Golebiowski, Robert Koralewski, Wojciech J. Czestkowski, Krzysztof Matyszewski, Sylwia Olejniczak, Jacek Olczak, Paul Beckett
-
Publication number: 20160090639Abstract: The present invention relates to a method for selection or screening of hDIS3 PIN domain inhibitors, yeast strain and cell line used in such methods It also relates to new therapeutic agents selected hDIS3 PIN domain inhibitors and uses thereof in the treatment of cancers having mutations inhDIS3 RNB domain, especially multiple myeloma. The invention also relates to composition comprising new therapeutic agent hDIS3 PIN domain inhibitor and method for inducing synthetic lethality in a cancer cell.Type: ApplicationFiled: May 20, 2014Publication date: March 31, 2016Inventors: Andrzej DZIEMBOWSKI, Rafal TOMECKI, Karolina DRAZKOWSKA, Roman SZCZESNY, Krystian STODUS, Weronika JONKO, Marcin NOWOTNY, Adam GOLEBIOWSKI, Jacek OLCZAK